ABSTRACT Candida auris is an emerging multidrug-resistant fungal pathogen causing nosocomial and invasive infections associated with high mortality. C. auris is commonly misidentified as several different yeast species by commercially available phenotypic identification platforms. Thus, there is an urgent need for a reliable diagnostic method. In this paper, we present fast, robust, easy-to-perform and interpret PCR and real-time PCR assays to identify C. auris and related species: Candida duobushaemulonii, Candida haemulonii, and Candida lusitaniae. Targeting rDNA region nucleotide sequences, primers specific for C. auris only or C. auris and related species were designed. A panel of 140 clinical fungal isolates was used in both PCR and real-time PCR assays followed by electrophoresis or melting temperature analysis, respectively. The identification results from the assays were 100% concordant with DNA sequencing results. These molecular assays overcome the deficiencies of existing phenotypic tests to identify C. auris and related species.
C
andida auris is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality. It was first described in 2009 after being isolated from the external ear discharge of a patient in Japan (1) . Since then, C. auris infections have been reported from South Korea (2, 3), India (4-6), Pakistan (5), Kuwait (7), Israel (8) , South Africa (5, 9), the United Kingdom (10-12), Spain (13) , the United States (14, 15) , Colombia (16) , and Venezuela (5, 17) . The Centers for Disease Control and Prevention (CDC) and other research groups reported that almost all C. auris isolates are highly resistant to fluconazole, with the other azoles showing variable antifungal activity and isavuconazole and posaconazole being the most active ones. Moreover, up to one-third were resistant to amphotericin B, and a few were resistant to echinocandins. Some isolates demonstrated elevated MICs to all three major antifungal classes (azoles, echinocandins, and polyenes), indicating that treatment options against these multidrug-resistant isolates would be limited (18) (19) (20) . C. auris is of great concern to public health agencies, due to the possibility that biologic and epidemiologic factors could trigger an even more extensive worldwide emergence of C. auris infections (21) . Therefore, it is important for clinical microbiology and public health laboratories to rapidly and accurately identify this organism to help prevent health care-associated outbreaks and improve survival among infected patients by enabling appropriate early antifungal therapy implementation (22, 23) .
C. auris is phenotypically close to Candida haemulonii (1) . It was reported that laboratories worldwide, relying on commercially available phenotypic platforms for yeast identification, commonly misidentify C. auris as C. haemulonii but also as several other yeast species (C. famata, C. guilliermondii, C. lusitaniae, C. parapsilosis, C. sake, Rhodotorula glutinis, and Saccharomyces cerevisiae) (18, 22, 24, 25) . Moreover, some clinical laboratories do not identify all Candida to the species level, placing C. auris isolates in the "other Candida spp." category (18). Thus, the prevalence of C. auris is probably significantly underestimated due to unreliable identifications (4, 18, 25) .
Given the current diagnostic urgency surrounding this pathogen, the aim of this work was to develop molecular-based methods that can quickly and accurately identify C. auris and related species (C. duobushaemulonii, C. haemulonii, and C. lusitaniae). The performance of the proposed methodology was evaluated using a comprehensive panel of clinical isolates with a wide spectrum of variable fungal species.
RESULTS
Primer design. The specific primers enabling the identification of C. auris and related species, C. duobushaemulonii, C. haemulonii, and C. lusitaniae are listed in Table  1 . The designed amplicons cover a fragment of 5.8S, all of ITS2, and a fragment of 28S. CauF and CauR primers were designed to selectively amplify a 163-bp-long PCR product specific for C. auris only. CauRelF and CauRelR primers were designed to selectively amplify PCR products from either C. auris, C. duobushaemulonii, C. haemulonii, or C. lusitaniae. Amplified fragments differ in length (215 bp, 208 bp, 197 bp, and 203 bp, respectively) and composition and can be easily distinguished upon melting curve analysis.
Candida auris-specific PCR and real-time PCR assays. A 163-bp PCR product specific for Candida auris was observed for all 44 C. auris DNA samples. No PCR products were detected for other yeast and mold isolates or human DNA (100% sensitivity and 100% specificity). Moreover, robust and reproducible amplicons were observed for all isolates when DNA extracts were replaced with a direct single-colony pick in the established assay (Fig. 1) .
Similar results were obtained when real-time PCR was applied, as an amplicon with a melting temperature (T m ) of 85.1 Ϯ 0.2°C, corresponding to C. auris, was observed only for 44 C. auris DNA samples and not for any other fungal or human DNA samples ( Fig. 2 and Table 2 ). The limit of detection (LOD) for the C. auris-specific assay was established at the level of 10 CFU/reaction (threshold cycle [C T ], 28.61 Ϯ 0.25). The accuracy of the assay was confirmed by a proficiency test against a panel of 46 isolates (Table 3 ). The distribution of the amplicons' melting temperatures obtained for C. auris isolates is presented in Fig. 3 .
Candida auris related-species-specific real-time PCR assay. PCR products were observed for the following DNA samples: 7 C. haemulonii isolates (T m , 84.8 Ϯ 0.2°C), 44 C. auris isolates (T m , 85.6 Ϯ 0.15°C), 6 C. duobushaemulonii isolates (T m , 86.2 Ϯ 0.1°C), and 6 C. lusitaniae isolates (T m , 87.6 Ϯ 0.1°C). No PCR products were detected for other yeast and mold isolates or human DNA (100% sensitivity and 100% specificity) (Fig. 4 and Table 2 ). The LOD for the C. auris related species-specific assay was established at the level of 1,000 CFU/reaction (C T , 27.83 Ϯ 0.87). The accuracy of the assay was confirmed by testing a proficiency panel of 46 isolates (Table 3 ). The distribution of the amplicons' melting temperatures obtained for C. haemulonii, C. auris, C. duobushaemulonii, and C. lusitaniae isolates is presented in Fig. 5 .
DISCUSSION
In 2016, the CDC released an alert informing of an emerging pathogen, Candida auris, that is causing invasive infections (18), due to the challenging identification, common multidrug resistance, and outbreaks of this pathogen in health care settings (15) .
A rapid and accurate identification of C. auris is important for not only the appro- 
TABLE 3 Proficiency panel results of Candida auris-specific and Candida auris related-species-specific assays

Species
Candida auris-specific real-time PCR
Candida auris related-speciesspecific real-time PCR
No. of isolates detected/no. tested T m (°C)
No. of isolates detected/no. tested T m (°C) C. auris 9/9 (C T , 18.5
25). Nowadays, proper identification of Candida species requires the application of specialized methods such as matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) or molecular identification based on sequencing the D1-D2 region of the 28S ribosomal DNA. However, due to the lack of C. auris entries in the FDA-approved libraries, it remains unidentified by Bruker Biotyper and Vitek-MS, and only when an additional research use only (RUO) library containing C. auris is incorporated can correct identification of this organism be obtained by both MALDI systems (25, 27) . In this study, we addressed the challenging identification of Candida auris. We present both conventional and real-time PCR assays that allow specific identification of C. auris and related species (C. duobushaemulonii, C. haemulonii, and C. lusitaniae) within 2 (real-time PCR and colony PCR) to 2.5 (conventional PCR) hours. To meet different diagnostic needs, we proposed two assays of different specificity ranges; the first assay identifies C. auris only, while in the second assay, C. auris, C. duobushaemu-lonii, C. haemulonii, and C. lusitaniae can be identified and distinguished from each other. The differential specificities of the assays were obtained by a detailed analysis of rDNA sequences deposited in the NCBI nucleotide database that enabled the design of highly specific primers. Using 140 fungal isolates and human genomic DNA, we were able to identify C. auris isolates with 100% accuracy in all developed assays. Moreover, in C. auris related-species-specific real-time PCR, signature melting profiles and corresponding T m values were generated for C. auris, C. duobushaemulonii, C. haemulonii, and C. lusitaniae, enabling their unambiguous discrimination. Excellent results were achieved with both assays during the development phase, as well as during the proficiency panel validation.
In summary, we have developed two rapid, accurate, easy-to-perform and interpret molecular diagnostic assays to identify C. auris and related species (C. duobushaemulonii, C. haemulonii, and C. lusitaniae) that overcome the deficiencies of existing phenotypic assays. Moreover, we expect that in the future, this diagnostic platform may be adjusted for the direct detection of C. auris in swabs from patients and from the hospital environment.
